The NephroCheck Test (and alternative technologies identified during scoping) to help assess the risk of acute kidney injury for people who are critically ill

The purpose of this assessment is to review the current evidence on the diagnostic accuracy, prognostic accuracy, impact on clinical
outcomes and cost-effectiveness of novel biomarkers (NephroCheck test, ARCHITECT Urine NGAL assay, NGAL plasma test and NGAL
urine test) for the assessment of AKI in critically ill patients who are considered for critical care admission.